xience

In diabetic patients, Everolimus eluting stents could perform better than Paclitaxel eluting stents

Original title: Safety and Efficacy of Everolimus-Eluting Stents Versus Paclitaxel-Eluting Stents in a Diabetic Population Reference: Ana Laynez et, al. Catheterization and Cardiovascular Intervention 81:759-765 (2013) Everolimus eluting stents have already been compared with paclitaxel eluting stents in the general population, and they have proved to perform best, especially as regards revascularization and in-stent thrombosis.  However, these data...

Bioresorbable stents produce more occlusion of the small side branches

Original title: Incidence and Short-Term Clinical Outcomes of Small Side Branch Occlusion Alter Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold Reference: Takashi Muramatsu et al. J Am Coll Cardiol Intv 2013;6:247–57. Small Side Branch Occlusion (SBO) during coronary angioplasty has been associated with periprocedural infarction. Among the factors that cause SBO are carina displacement, plaque displacement and artery...

It takes more patience to implant stents.

Original title: Duration of Balloon Inflation for Optimal Stent Deployment: Five Seconds Is Not Enough. Reference: Thomas Hovasse et al. Catheterization and Cardiovascular Interventions 81:446–453 (2013). Adequate stent expansion and apposition to the vessel wall is essential to optimize the results of percutaneous transluminal coronary angioplasty (PTCA). If the above is not adequate, it increases the risk of...

Chronic Total Occlusions, challenging but very possible

Original title: Predictors of Reocclusion After Successful Drug-Eluting Stent–Supported Percutaneous Coronary Intervention of Chronic Total Occlusion. The Florence CTO PCI Registry. Reference: Renato Valenti et al. J Am Coll Cardiol 2013; article in press. Previous registry data have shown a reduction in mortality rates in patients with successful recanalization of a Chronic Total Occlusion (CTO) compared to patients...

Future second-generation stents, today.

Original title: First Serial Assessment at 6 Months and 2 Years of the Second Generation of Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold A Multi-Imaging Modality Study. Reference: John Ormiston et al. Circ Cardiovasc Interv. 2012;5:620-632. The first bioabsorbable stents eluting everolimus showed a 6-month delayed recoil resulting in late lumen loss of 0.44 mm, (intermediate between a metal stent...

Top